Triple synchronous primary lung cancer

Zardo, Patrick; Krüer, Thomas; Schiffmann, Stefan; Freermann, S; Fischer, Stefan

doi:10.1177/0218492313495550

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior to discussion of treatment, it should be appreciated that staging synchronous or metachronous primary lung cancers requires diagnostic acumen. Several case reports underline the importance of thorough staging, to allow for appropriate treatment to be offered to patients who could be easily mistaken to have multicentric disease or intrapulmonary metastases and thereby be denied radical treatment [ 8 ]. For similar reasons, lower survival rates have been associated with a short (< 2 years) interval between detection of first and second primary tumours in metachronous lung cancer [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD

Duimering¹,

Gabos²,

Debenham³

2015

Cureus

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT) has not been widely employed in the treatment of limited-stage (LS) small-cell lung cancer (SCLC), although SBRT finds particular utility in patients medically unfit to undergo surgical resection or radiotherapy with conventional fields. The authors present the case of a 61-year-old female smoker with severe chronic obstructive pulmonary disease (COPD), diagnosed incidentally with LS-SCLC. Concurrent chemoradiotherapy was contraindicated by her poor pulmonary function, and she was treated radically with four cycles of cisplatin and etoposide chemotherapy. This was followed by prophylactic cranial irradiation and consolidative SBRT (48 Gy in 4 fractions) to the residual tumour, which achieved a complete clinical response. Fifteen months following the patient’s initial diagnosis, a metachronous Stage IA contralateral non-small cell lung cancer (NSCLC) was incidentally diagnosed and was treated with SBRT (48 Gy in 4 fractions). Although studies have established that the incidence of a second lung cancer is higher in patients with previous SCLC, this case is unique in that both primaries were treated with SBRT.

show abstract

Section: Discussionmentioning

confidence: 99%

SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD

Duimering¹,

Gabos²,

Debenham³

2015

Cureus

View full text Add to dashboard Cite

show abstract

<p>Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy</p>

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

The prevalence of cancer remains high. With the improvement of diagnosis and treatment level and the increase of cancer survivors after treatment, multiple primary tumors are more common than before. The diagnosis and treatment of synchronous multiple primary tumors is more complicated than that of single or metachronous multiple tumors, and patients also suffer more. Because of the different conditions of these patients, lack of large-scale clinical observation data, it is necessary for clinicians to make realistic decisions on the specific conditions of patients. It is a challenge for clinicians to apply the advances of modern medicine to the diagnosis and treatment of such patients so as to prolong their survival time and improve their quality of life. This report describes the survival of an advanced elderly patient with lung, prostate and bladder cancer after receiving targeted therapy-based comprehensive treatment.

show abstract

Triple synchronous primary lung cancer

Cited by 2 publications

References 8 publications

SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD

SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD

<p>Clinical treatment of advanced synchronous triple primary malignancies: comprehensive treatment based on targeted therapy</p>

Contact Info

Product

Resources

About